Schering Likely To Play Up Saphris' Safety In Q4 Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Clearance for schizophrenia and bipolar disorder in one fell swoop marks a first in the crowded class of atypical anti-psychotics.
You may also be interested in...
Dainippon Sumitomo Submits Lurasidone NDA, Preps For Marketing Scramble
WASHINGTON - Dainippon Sumitomo submitted an NDA to U.S. FDA for its atypical antipsychotic lurasidone for schizophrenia, and the company is hoping its newly acquired Sepracor sales force is up to the challenge in a crowded, but still fruitful, market
Dainippon Sumitomo Submits Lurasidone NDA, Preps For Marketing Scramble
Company will use newly acquired Sepracor sales force for the atypical antipsychotic.
Dainippon Sumitomo Submits Lurasidone NDA, Preps For Marketing Scramble
Company will use newly acquired Sepracor sales force for the atypical antipsychotic.